Key Takeaways
- Revenue up 54% YoY, but margin pain is the real story: Total revenue hit INR 77 crores, yet absolute EBITDA fell from INR 17 crores to INR 13 crores YoY as HMDS margins compressed and capacity growth outpaced volume uptake.
- Bromides and bromobenzene are the new growth engine: The bromide business delivered INR 29 crores on robust demand, while newly added bromobenzene contributed INR 7 crores; together they offset persistent weakness in the legacy HMDS and CMIC pharma portfolio.
- HMDS margins are structurally resetting lower: Management acknowledged that the cost-plus conversion model is under pressure and margins, enjoyed for over five years, should now start reducing; no visibility on a return to prior profitability.
- New products are coming, but the timeline is gradual: Guanine commissioning is expected in Q4 FY23, the P10 plant in Q1 FY24, and full P10 ramp-up only in FY25; management declined to give any margin or revenue projections for the next financial year.
- What to watch next quarter: Whether Guanine actually commissions and starts contributing to the P&L, the trajectory of HMDS volumes and margins, and any sign that the promised pharma demand revival is materializing.
HMDS: The Margin Reset
- Demand weakness is structural, not cyclical: Indian pharma consumption of HMDS is dropping, and imports into India have come down, indicating overall actual demand for the product has decreased. Exports, now roughly 50% of HMDS revenue, are entirely for non-pharma applications.
- China competition is manageable, but not the problem: Management argued that Chinese import duties neutralize cost competitiveness, so Chemcon can compete in India and in other markets where duties apply. The real issue is shrinking end-user demand from products like penicillin, not competitive displacement.
- Margin model under pressure: The cost-plus conversion-based model keeps changing and is not fixed; this quarter saw pressure on that model, and margins are expected to remain lower for the current quarter and maybe one more quarter. Prices are nearly stable QoQ, so the squeeze is in the conversion spread.
- Volume outlook modestly better: Q4 FY23 HMDS volumes are expected to be better than Q3, but management offered no timeline for a return to good profitability on the product.
Kamal Aggarwal: "HMDS, cannot comment that the margins will remain consistent, because we have been enjoying this margin since more than five years. I feel now it should start reducing to some extent from maybe marginally."
Bromides & Bromobenzene: The Offset
- Bromide business firing on all fronts: Revenue of INR 29 crores, roughly 38% of the total, driven by significant volume growth from healthy demand and better sourcing of key raw materials. Management is very confident the momentum in oil field chemicals sales will be sustained through the current year and next year, backed by raw material import contracts.
- Raw material contracting de-risks supply: A one-year contract covering 35% to 40% of total raw material requirement for the calendar year has been signed; the remaining 60% is domestically sourced on an ad-hoc basis, and management is working on contracting that portion as well, though some pressure on domestic availability is expected.
- Bromobenzene off to a strong start: The newly added organic bromide contributed INR 7 crores in Q3 FY23 from the P9 facility (2,400 TPA capacity). Full-year FY23 revenue may be marginally less than INR 40 crores, but good volumes and exports are flowing, and inquiries from global agrochemical players are strong.
- Utilization ramp in FY24: Bromobenzene utilization is expected at about 75% in FY24, with operating margins expected above 30%. Capacity doubling is not immediate but will be added in time.
New Product Pipeline: Guanine & P10
- Guanine is the nearest catalyst: The new product, with a value around $23 and expected margin around 25%, is awaiting final local authority approvals. Management hopes commissioning happens within Q4 FY23, with figures starting to reflect in the P&L within the current quarter or next, and better sales expected in FY24.
- Modular plant enables fast scaling: The Guanine facility is modular; if demand picks up, the company can add multiple new plants rather than just debottlenecking. Maximum one quarter is needed to run the facility at full capacity, with 85% to 90% utilization expected in FY24.
- P10 plant on track for Q1 FY24: The expansion will add a few other pharma chemicals primarily imported into India. No regulatory approval is required beyond the Pollution Control Board clearance already obtained. Full capacity is expected in FY25, with a capex-to-topline multiple of 3.5x to 4x.
- Product names withheld: Management declined to disclose which products will be manufactured at P10, stating it is not the right time.
- Two shelved products: Commercial production of low-volume 4 CBC and 2,5 DHT has been shelved; the facility will be partly utilized for CMIC depending on demand.
CMIC: Modest Improvement, Modest Outlook
- Marginal recovery in Q3: CMIC contributed INR 11 crores, roughly 15% of total revenue, with marginal volume growth and better realization. Domestic pharma demand remained soft for some months, but purchase orders from China are expected to improve export revenue.
- Margin resilience expected: Management stated CMIC can go with 30% margin even in the present era under pressure, while HMDS margins are expected to be lower for the current quarter or maybe one more quarter.
Strategy: Diluting Concentration, Adding Locations
- Deliberate product diversification: Management wants to dilute concentration on HMDS and CMIC specifically; future growth will be driven by a mixture of products rather than one or two dedicated products. The bromobenzene and Guanine additions, plus the P10 pipeline, are the first visible steps.
- Multi-location footprint beginning: Agricultural land has been purchased roughly 5 to 6 km from the existing location and given for conversion to non-agriculture. The intent is to dilute single-location concentration and enable multi-location working, though planning will start only after permissions and may take a couple of years. An understanding has also been entered into for land at Raichur for future expansion.
- More capex beyond P10: Expansion will happen at the existing facility and at other locations including Raichur in FY24. New products are targeted at 30% to 40% margins or a payback period of less than one year.
- Re-engineering, not R&D: Management clarified the company does not do R&D on chemistry, which remains pre-performed; its engineering expenses are on re-engineering processes, a distinction that shapes the innovation bandwidth.
Kamal Aggarwal: "We want to dilute our concentrations on these two products in particular... We don't want to concentrate on particular products."
Margin Trajectory & The Information Gap
- Gross margin is where the damage sits: The entire EBITDA decline came through gross margins, while other costs remained flat year-on-year. Pressure was on both raw material pricing and finished product pricing, with the differential margins that used to work coming down.
- HMDS is the principal drag: The margin pressure was concentrated in HMDS, where the conversion spread compressed. Management expects HMDS margins to remain lower for the current quarter or maybe one more quarter, with no visibility on a recovery to prior profitability levels.
- Offset coming from new products, but timing is uncertain: As bromobenzene, Guanine, and eventually P10 products scale up, management expects a return to normal profitability levels of 30% operating margins. However, it declined to commit to any timeline or to say whether FY24 operating margin will be in the 25% to 30% range.
- Management asks for patience: The present one or two quarters of margin pressure should not be considered a base for business deviation; a couple more quarters are needed to understand the direction. Margins should be maintained or there can be marginal pressure, with a reduction from 30% to 28% or 25% possible, but volume or new products should take care of that.
Kamal Aggarwal: "This period, in the present one or two quarters, if you see the margins, there have been a pressure that should not be considered as a base for the business deviation. We need to wait for a couple of quarters more to understand the line or the direction for the margins."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Guanine commissioning | Awaiting final local authority approvals; figures to start reflecting in P&L | Q4 FY23 (no further delay expected) |
| Guanine ramp-up | Run at full capacity; 85%–90% utilization expected in FY24 | Maximum one quarter from commissioning |
| P10 plant commissioning | Commercial production start; no regulatory approval needed beyond PCB clearance already obtained | Q1 FY24 |
| P10 plant full capacity | Full ramp-up | FY25 |
| Bromobenzene utilization | ~75% utilization expected | FY24 |
| Bromide business momentum | Sustained oil field chemicals sales, backed by raw material import contracts | Current year and next year |
| HMDS Q4 volumes | Better than Q3 volume | Q4 FY23 |
| HMDS margins | Expected to remain lower | Current quarter and maybe one more quarter |
| Raw material contract coverage | One-year contract signed covering 35%–40% of total requirement; working on contracting the remaining domestic portion | Calendar year 2023 |
| New land development | Planning starts after non-agriculture conversion permissions | May take a couple of years |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue | ₹77 cr, +54% YoY |
| Domestic revenue share | ~40%, international ~60% |
| EBITDA | ₹14 cr, margin 17.6% |
| Net profit | ₹11 cr, margin 14.9% |
| Total production volume | 2,323 metric tons, vs 1,333 metric tons in Q3 FY22 |
| HMDS revenue | ₹27 cr, ~36% of total revenue |
| CMIC revenue | ₹11 cr, ~15% of total revenue |
| Bromide revenue | ₹28 cr, ~38% of total revenue |
| Bromobenzene revenue | ₹7 cr, ~9% of total revenue |
| Bromobenzene volume sold | 252 metric tons |
| HMDS current price | ~₹650, nearly stable QoQ |
| CMIC current price | ~₹400, nearly stable QoQ |
| Guanine capacity | 50 tons per month, 600 tons per year |
| Guanine expected margin | ~25% |
| P10 plant capex | ₹22 cr, commissioning expected Q1 FY24 |